JHCO Tokyo Yamate Medical Center

Shinjuku-ku, Tokyo 169-0073

0 studies enrolling now · 4 studies all time

What they study most

Crohn's Disease, Ulcerative Colitis

Studies at this site

• A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis — Completed
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease — Completed